Related Experiment Video
Updated: Jul 16, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Current state-of-the-art and potential future therapeutic drugs against COVID-19
Ailong Sha1,2, Yi Liu2, Haiyan Hao3
1School of Teacher Education, Chongqing Three Gorges University, Chongqing, China.
Abstract:
The novel coronavirus disease (COVID-19) continues to endanger human health, and its therapeutic drugs are under intensive research and development. Identifying the efficacy and toxicity of drugs in animal models is helpful for further screening of effective medications, which is also a prerequisite for drugs to enter clinical trials. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invades host cells mainly by the S protein on its surface. After the SARS-CoV-2 RNA genome is injected into the cells, M protein will help assemble and release new viruses. RdRp is crucial for virus replication, assembly, and release of new virus particles. This review analyzes and discusses 26 anti-SARS-CoV-2 drugs based on their mechanism of action, effectiveness and safety in different animal models. We propose five drugs to be the most promising to enter the next stage of clinical trial research, thus providing a reference for future drug development.
Insights
This review analyzes 26 drugs for treating COVID-19, evaluating their effectiveness and safety in animal models. Five promising antiviral therapies are identified for further clinical trials.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- The COVID-19 pandemic necessitates urgent development of effective therapeutic drugs.
- Animal models are crucial for assessing drug efficacy and toxicity before human clinical trials.
- Understanding SARS-CoV-2 mechanisms, including S protein entry and viral replication involving RdRp and M protein, is key to drug discovery.
Purpose of the Study:
- To review and analyze 26 drugs targeting SARS-CoV-2.
- To evaluate the efficacy and safety profiles of these drugs in various animal models.
- To identify the most promising drug candidates for advancing to clinical trials.
Main Methods:
- Systematic review and analysis of existing literature on 26 anti-SARS-CoV-2 drugs.
- Assessment of drug mechanisms of action against SARS-CoV-2.
- Evaluation of drug effectiveness and toxicity data from preclinical animal studies.
Main Results:
- Detailed analysis of 26 antiviral agents targeting different stages of the SARS-CoV-2 lifecycle.
- Comparative assessment of drug performance across diverse animal models.
- Identification of five drug candidates demonstrating favorable efficacy and safety profiles.
Conclusions:
- Five drugs show significant promise for treating COVID-19 and warrant progression to clinical trials.
- Preclinical data from animal models provides a critical foundation for selecting effective and safe therapeutic agents.
- This review offers valuable insights for guiding future research and development of anti-SARS-CoV-2 therapies.
More Related Videos
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Drug Therapy
Antianxiety Medications
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Heart Failure Drugs: Inotropic Agents
Drug Classes and Categories

